MedTrace Logo

The Effect of Combined Speech and Music-therapy on the Speech Characteristics of People With Parkinson's Disease (PD)

NCT04966689 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 33

Last updated 2023-04-04

No results posted yet for this study

Summary

Speech and voice disorders are observed in almost 90% of patients with PD during their course of illness. Reduced voice pitch inflections or monotone speech, reduced vocal loudness, prosody disorders, the imprecise articulation of the consonants, hoarseness, and breathy voice is also observed in patients with PD; these symptoms often lead to reduced speech intelligibility. The aim of this study will to investigate the possible changes in the voice and speech features in people with PD after a combined speech and music therapy using Telerehabilitation.

Conditions

  • Speech Disorders
  • Voice Disorders
  • Parkinson Disease

Interventions

BEHAVIORAL

combined speech and music therapy

he telerehabilitation intervention that include both speech therapy and music therapy at the same time

BEHAVIORAL

speech therapy

A behavioural speech therapy program including breathing exercises, loudness, pitch, and intelligibility which are adapted from Lee Silverman Voice Treatment (LSVT) and voice exercises Which is delivered through telerehabilitation

BEHAVIORAL

music therapy

music exercises Will be designed based on the music therapy protocols of previous studies Which is delivered through telerehabilitation

Sponsors & Collaborators

  • Iran University of Medical Sciences

    lead OTHER

Principal Investigators

  • Reyhaneh Mohammadi · Iran university of medical science

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
40 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-07-17
Primary Completion
2022-01-07
Completion
2022-01-30

Countries

  • Iran

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04966689 on ClinicalTrials.gov